123 results
8-K
EX-1.1
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
9:06am
, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company … ) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
424B5
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
Prospectus supplement for primary offering
7:00am
;
the potential attributes and benefits of our product candidates, and if approved, our products;
our ability to manufacture rilparencel, our lead … ;
the potential attributes and benefits of our product candidates, and if approved, our products;
our ability to manufacture REACT, our lead product
424B5
PROK
ProKidney Corp - Ordinary Shares
10 Jun 24
Prospectus supplement for primary offering
5:13pm
activities;
the potential attributes and benefits of our product candidates, and if approved, our products;
our ability to manufacture rilparencel … ability to manage our growth effectively;
the success, cost and timing of our product development activities;
the potential attributes and benefits
8-K
EX-99.2
PROK
ProKidney Corp - Ordinary Shares
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
benefits and impact of the Company’s products, if approved, potential regulatory approvals, and the size and potential growth of current or future markets
8-K
PROK
ProKidney Corp - Ordinary Shares
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
kidney function in patients with moderate to severe CKD, the potential QP Declaration of Equivalence to EU GMPs, the potential benefits and impact
8-K
EX-99.1
lq7 imabtd
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
8-K
EX-99.1
ziy2uw4 tdug
29 May 24
RMCL-002 Final Analysis Developing Solutions for Dialysis Prevention May 2024
7:04am
8-K
EX-99.1
dyutl
10 May 24
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
7:05am
8-K
EX-99.1
0p0 7nq4u
25 Mar 24
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
4:07pm
8-K
EX-10.1
6ltyrq7j
25 Mar 24
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
4:07pm
8-K
EX-99.1
49lbnwww 2twf
21 Mar 24
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
8:00pm
8-K/A
EX-10.1
0t1jgs2okbd gi
18 Mar 24
Departure of Directors or Certain Officers
4:09pm
8-K/A
EX-10.2
1lur00v1m3hy k8c2
18 Mar 24
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
k2tehyzl4m8v68sl9
26 Jan 24
Regulation FD Disclosure
12:00am
8-K
EX-1.1
h776j1 kmicg
19 Jan 24
Entry into a Material Definitive Agreement
4:19pm